Can laboratory testing for antiphospholipid antibody syndrome be performed while the patient is receiving anticoagulation therapy?

Can Antiphospholipid Antibody Testing Be Performed While on Anticoagulation?

Yes, antiphospholipid antibody testing can be performed while on anticoagulation, but the approach differs significantly based on which antibodies you're testing and which anticoagulant the patient is taking. 1

Testing Strategy Based on Antibody Type

Anticardiolipin (aCL) and Anti-β2-Glycoprotein I (aβ2GPI) Antibodies

These solid-phase immunological assays are NOT affected by anticoagulation and can be reliably performed at any time. 1 This includes patients on:

• Warfarin/VKA
• DOACs (rivaroxaban, apixaban, dabigatran, edoxaban)
• LMWH
• Unfractionated heparin

The antibodies are measured by ELISA or automated systems and anticoagulants do not interfere with these immunological assays. Test for both IgG and IgM isotypes concurrently. 1

Lupus Anticoagulant (LA) Testing

This is where anticoagulation creates major problems because LA testing relies on clotting assays that are directly affected by anticoagulants. 1 The 2025 ISTH guidance provides specific strategies:

For Patients on DOACs:

• Use pretest DOAC removal procedures (commercial DOAC removal agents or activated charcoal) 1
• Perform LA testing both pre- and post-DOAC removal to compare results 1
• Compare clotting times before and after removal to prevent misinterpretation 1
• Alternative: Use TSVT/ET (Taipan snake venom time/ecarin time) during anti-Xa DOAC therapy, though sensitivity is not 100% 1
• Sampling during DOAC trough periods is an option but doesn't guarantee lack of interference 1

Critical caveat: Even after DOAC removal, if clotting times remain prolonged, residual DOAC interference cannot be ruled out. 1

For Patients on Warfarin/VKA:

• LA testing during VKA is unreliable and should be interpreted with extreme caution 1
• Results may yield false positives or false negatives 1
• Ideally, discontinue VKA for 1-2 weeks (with or without LMWH bridging) before testing 1
• If testing must be done on VKA, retest after discontinuation to verify results 1
• Alternative: Use TSVT/ET which can be performed during VKA therapy 1
• LA should be reported as "absent with comment on potential false negatives when tested during VKA therapy" 1

For Patients on LMWH:

• Sample during trough period (12-24 hours after last dose) 1

Practical Clinical Algorithm

Step 1: Determine urgency of diagnosis

• If stopping anticoagulation is unsafe (recent thrombosis, high thrombotic risk), proceed with testing on anticoagulation
• If diagnosis can wait and patient is stable, consider holding anticoagulation temporarily

Step 2: Order comprehensive testing regardless of anticoagulation status

• aCL IgG and IgM
• aβ2GPI IgG and IgM
• LA testing (with appropriate modifications below)

Step 3: For LA testing specifically:

• On DOAC: Use DOAC removal procedure with pre/post comparison OR use TSVT/ET
• On warfarin: Either discontinue for 1-2 weeks OR use TSVT/ET OR test with explicit caveat about unreliability
• On LMWH: Test during trough period

Step 4: Interpret results in clinical context

• Triple positivity (LA + aCL + aβ2GPI) indicates highest risk 1
• If only aCL/aβ2GPI positive while on anticoagulation, this is reliable 1
• If LA testing is unreliable due to anticoagulation, consider aPS/PT (antiphosphatidylserine/prothrombin) antibodies as alternative 1

Step 5: Confirm positive results

• Repeat testing at least 12 weeks later 1, 2
• Same antibodies must be positive on repeat testing

Common Pitfalls to Avoid

1. Don't assume negative LA on anticoagulation rules out APS - it may be a false negative 1
2. Don't use DOAC removal agents on samples from patients not known to be on DOACs 1
3. Don't interpret borderline LA results on anticoagulation as definitive - minor changes from DOAC removal can flip results from positive to negative or vice versa 1
4. Don't forget that results near cutoff values have 10% imprecision - interpret cautiously 1
5. Don't test during acute thrombosis - antibody levels may be falsely low due to consumption at the thrombotic site; retest at distance from acute event 1

When Testing Cannot Wait

In high-risk situations where anticoagulation cannot be stopped (e.g., recent thrombosis, mechanical heart valve), proceed with full testing but document the limitations clearly in the medical record. 1 The solid-phase antibody results (aCL and aβ2GPI) will be reliable, and if these are positive, they provide valuable diagnostic and risk stratification information even without definitive LA results. If the patient is double-positive for aCL and aβ2GPI with concordant isotype, this significantly increases confidence in APS diagnosis even without LA confirmation. 1

The laboratory should report LA results with explicit warnings about anticoagulant interference, and close collaboration between laboratory and clinician is essential for proper interpretation. 1